Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 65 and up

Buprenorphine for pain relief in older adults with broken bones in the ED

Official title: Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department: a Randomized Controlled Study

Run by Cooper Norcross Health · NCT07430345 · Data updated 2026-11-12

This study tests whether buprenorphine can safely and effectively relieve pain in older adults with acute fractures, compared with hydromorphone.

More Fracture trials

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages65 Years and up
SexAll
Enrollment48 (estimated)
SponsorCooper Norcross Health
Academic / other
Locations1 site (Camden, New Jersey)
StatusRecruiting
StartedMay 7, 2026
Main results expectedDecember 2026
Study endsJanuary 2027
Registry record updatedJune 29, 2026
Trial IDNCT07430345 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 65 years and older with an acute fracture presenting to the ED, able to consent or have a surrogate decision-maker.

Probably not a fit

Patients who do not experience adequate pain relief or who have adverse reactions to buprenorphine or hydromorphone may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study in older adults with suspected or confirmed acute fractures in the emergency department compares buprenorphine and hydromorphone for pain control over 48 hours. It is conducted in two phases (Phase 1 and Phase 2) to assess safety and efficacy in a geriatric population. Buprenorphine is a partial opioid with potential advantages in older patients, including fewer respiratory effects and no dose adjustments for liver or kidney issues. The trial will measure pain scores and adverse events after administration of the two drugs. Eligible participants are adults aged 65 and older seeking ED care for fracture who can consent or have a surrogate decision-maker.

Why it matters

Potential benefit: If successful, buprenorphine could provide effective pain relief with fewer side effects for older adults with fractures.

How similar studies have gone: Prior studies suggest buprenorphine can match or exceed efficacy of full agonists in acute pain, but older adults have been underrepresented.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 65 years or older
* Emergency Department patient
* Diagnosis of suspected or confirmed acute fracture
* Numerical Rating Scale 4 or greater at time of presentation
* Must be able to give informed consent or have a surrogate decisionmaker to provide informed consent
* Subjects who may require a surgical procedure are eligible for enrollment, as given the low dose of buprenorphine, this is not anticipated to affect future anesthesia. If additional pain control is needed for surgical procedure, full agonist opioid can be used without contraindication.

Exclusion Criteria:

* Prior history of opioid use disorder
* Participants taking chronic opioid therapy (defined as opioids taken during the past month)
* Allergy to study medications
* Hemodynamic instability requiring immediate resuscitation
* Inability to consent and absence of surrogate decisionmaker

Where it's running

  • Cooper University Hospital
    Camden, New Jersey, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.